NCT05386550 2026-02-19
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
EMD Serono
Phase 3 Terminated
EMD Serono
Inovio Pharmaceuticals
Arbeitsgemeinschaft medikamentoese Tumortherapie
Tata Memorial Hospital